WO2020239356A1 - Composition pour la protection et la reparation de la barriere hematoencephalique (bhe) - Google Patents
Composition pour la protection et la reparation de la barriere hematoencephalique (bhe) Download PDFInfo
- Publication number
- WO2020239356A1 WO2020239356A1 PCT/EP2020/062081 EP2020062081W WO2020239356A1 WO 2020239356 A1 WO2020239356 A1 WO 2020239356A1 EP 2020062081 W EP2020062081 W EP 2020062081W WO 2020239356 A1 WO2020239356 A1 WO 2020239356A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- group
- use according
- monomers
- blood
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- composition for the protection and repair of the hematoencephalic barrier (BBB)
- the present invention relates to a pharmaceutical composition for its application as a medicament, in particular for its use for the protection of the blood-brain barrier.
- the present invention also relates to a pharmaceutical composition for its application as a medicament, in particular for its use for the repair and / or restoration of the blood-brain barrier.
- the present invention relates to a pharmaceutical composition for its application as a medicament, in particular for its use for the protection and / or repair and / or restoration of the blood-brain barrier.
- the present invention finds application in particular in the therapeutic, pharmaceutical and veterinary fields.
- references in parentheses refer to the list of references presented at the end of the text.
- the blood-brain barrier also called the blood-brain or blood-meningeal barrier, is made up of a monolayer of endothelial cells in the micro-vessels of the brain. These endothelial cells have tight junctions between them, thus limiting para- and trans-cellular exchanges between the blood compartment and the parenchymal compartment. Endothelial cells are surrounded by a basement membrane, astrocytic feet and pericytes thus strengthening the BBB (Sharif et al., 2018 [16]).
- the basal lamina underlying the cerebral endothelium actively participates in the dynamics of the BBB consists of 3 layers.
- the first synthesized by endothelial cells is characterized by the presence of laminin 4 and 5.
- the second is characterized by the presence of laminin -1 and -2, and is synthesized by astrocytes.
- the third, characterized by the presence of collagen IV, is found between the first two, it is formed by the two cell types.
- These three layers are also made up of different types of collagen, glycoproteins and proteoglycans, in particular heparan sulphates proteoglycans (HSPGs) (Cardoso et al., 2010 [4]).
- the basal lamina also contains many proteins,
- MMPs metalloproteases
- BBB protects neurons against factors present in the systemic circulation and maintains the internal environment of the central nervous system, necessary for good synaptic and neuronal functioning (Sharif et al., 2018 [16]).
- BBB brain diseases
- brain diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, stroke, encephalopathy chronic trauma, but also cerebral infections (Abdullahi et al., 2018 [1]; Sweeney et al., 2018 [19]; Erickson and Banks 2018 [5]).
- the BBB is also impaired in the presence of brain tumors as well as following brain irradiation as part of radiotherapy (Katherine Elizabeth Warren., 2018 [22]).
- the disruption of the BBB allows the influx into the brain of agents
- neurotoxic agents derived from blood, cells and microbial pathogens and is associated with inflammatory and immune responses, which can initiate and exacerbate multiple pathways of neuronal death (Sharif et al., 2018 [16]).
- BBB tight junctions and cell receptors; or to fight against causes of its permeability: inflammation; oxidation; activation of MMPs (Sifat et al., 2017 [17]).
- MMPs activation of MMPs
- BBB function of the BBB, for example after an injury and / or deterioration of said BBB.
- the object of the present invention is precisely to meet these needs by providing a pharmaceutical composition for its application or use as a medicament for the protection and / or repair and / or restoration, preferably functional, of the blood-brain barrier, said composition comprising
- A represents a monomer
- Y represents an O or N-sulfonate group and corresponding to one of the following formulas -R3OSO3R4, -R5NSO3R6, -R7SO3R8 in which:
- Ri, R3, R5 and R9 independently represent an aliphatic hydrocarbon chain, optionally branched and / or unsaturated and which optionally contains one or more aromatic rings with the exception of benzylamine and benzylamine sulfonate, R 2, R 4,
- Re and Re independently represent a hydrogen atom or an M + cation
- Rz and R 10 independently represent a bond, an aliphatic hydrocarbon chain, optionally branched and / or unsaturated
- a represents the number of monomers
- x represents the degree of substitution of monomers A by X groups
- y represents the degree of substitution of monomers A by groups Y.
- the object of the present invention is precisely to meet these needs by providing a pharmaceutical composition for its use as a medicament for the protection and / or repair and / or restoration, of functional preference of the blood-brain barrier, said composition comprising
- A represents a monomer
- Y represents an O or N-sulfonate group and corresponding to one of the following formulas -R3OSO3R4, -R5NSO3R6, -RySC Rs in which:
- Ri, R3, R5 and R9 independently represent an aliphatic hydrocarbon chain, optionally branched and / or unsaturated and which optionally contains one or more aromatic rings with the exception of benzylamine and benzylamine sulfonate, R 2, R 4, Re and Re independently represent a hydrogen atom or an M + cation, and Rz and R 10 independently represent a bond, an aliphatic, optionally branched and / or unsaturated hydrocarbon chain,
- a represents the number of monomers
- x represents the degree of substitution of monomers A by groups X
- y represents the degree of substitution of the A monomers by Y groups.
- BBB blood-brain barrier
- the inventors have surprisingly demonstrated that the use of the biocompatible polymer according to the invention advantageously allows, when the blood-brain barrier (BBB) has been altered, for example presents an inflammation and / or lesion and / or any known alteration those skilled in the art, whatever the cause or origin, to repair and / or strengthen and / or restore the blood-brain barrier (BBB).
- BBB blood-brain barrier
- the inventors have also surprisingly and unexpectedly demonstrated that the use of the polymer according to the invention advantageously makes it possible to accelerate and improve the functional recovery of the blood-brain barrier (BBB).
- BBB blood-brain barrier
- the inventors have demonstrated, surprisingly and unexpectedly, that when the alteration of the BBB has an effect on motor and / or cognitive functions, the use of the polymer according to the invention also makes it possible to accelerate and / or improve functional motor and cognitive recovery.
- protection of the blood-brain barrier is meant, for example, an improvement in the structure of the basement membrane of the blood-brain barrier and / or a stimulation of the endothelial cells of the blood-brain barrier and / or a strengthening of tight junctions of the blood-brain barrier .
- the protection of the blood-brain barrier allows, for example, protection of the latter from external attacks, for example from ionizing radiation, for example from X-rays, from gamma rays, from isotopic compounds, for example from xenobiotic compounds, various toxins. and pathogens.
- Protection of the blood-brain barrier may also allow the maintenance of homeostasis of the central nervous system, for example regulation of the ionic flow, and / or regulation of molecular and cellular flow, in particular between the blood compartment and the central nervous system. These flows can be deleterious for the central nervous system in the event of damage and permeability of said barrier.
- repair of the blood-brain barrier is meant, for example the reformation and / or improvement of the structure of the blood-brain barrier, for example when the structure of said barrier has been altered, for example due to an injury, an external aggression , for example a pathogen, a disease, due to inflammation and / or any event known to a person skilled in the art capable of altering and / or modifying the structure and / or function of the blood-brain barrier.
- This may be, for example, an acceleration of the healing of a lesion of the blood-brain barrier, a decrease in inflammation of the blood-brain barrier, scarring and / or improvement of the basement membrane of the brain.
- the blood-brain barrier and / or endothelial cells of the blood-brain barrier and / or tight junctions of the blood-brain barrier are examples of the blood-brain barrier.
- restoration of the blood-brain barrier is meant structural repair and / or reformation of the blood-brain barrier and restoration / improvement of the blood-brain barrier function, for example of the permeability of the blood-brain barrier and / or of any physiological function of the barrier hematoencephalic.
- monomer chosen from the group comprising sugars, esters, alcohols, amino acids or nucleotides.
- the monomers A constitute the building blocks of the polymers of formula I can be the same or different.
- the A monomers can be
- Ru and R 12 independently represent an oxygen atom, an aliphatic, optionally branched and / or unsaturated hydrocarbon chain, a heteroaryl group independently comprising one or more oxygen and / or nitrogen atoms, an aldehyde function, a carboxylic acid group, a diol, a substituted diol, a group of formula -Ri3- (X) n-Ru in which R 13 represents a C 1 to C 4 aliphatic carbon chain, optionally branched and / or unsaturated, X represents a heteroatom chosen from oxygen and nitrogen, is an integer ranging from 1 to 4 and Ru is a hydrogen atom, an aliphatic hydrocarbon chain, optionally branched and / or unsaturated, a heteroaryl group independently comprising one or more atoms of oxygen and / or nitrogen, an aldehyde function, a carboxylic acid group, a diol, a substituted diol.
- the combination of monomers can make it possible to form a polymeric backbone, for example a polymeric backbone of polyester, polyalcohol, polysaccharide, of the nucleic acid or protein type.
- polyesters it may be, for example, copolymers of biosynthesis or chemical synthesis, for example aliphatic polyesters or of natural origin, for example polyhydroxyalkonotes.
- the polysaccharides and their derivatives can be of bacterial, animal, fungal and / or plant origin. They may for example be single-chain polysaccharides, for example example polyglucoses, for example dextran, cellulose, beta glucan, or other monomers comprising more complex units, for example xanthans, for example glucose, mannose and glucuronic acid or else glucuronans and glucoglucuronan.
- polyglucoses for example dextran, cellulose, beta glucan
- monomers comprising more complex units for example xanthans, for example glucose, mannose and glucuronic acid or else glucuronans and glucoglucuronan.
- the polysaccharides of plant origin can be single chain, for example cellulose (glucose), pectins (galacturonic acid), fucans, starch or more complex such as alginates (galuronic and mannuronic acid) .
- the polysaccharides of fungal origin can be, for example, steroglucan.
- the polysaccharides of animal origin can be, for example, chitins or chitosan (glucosamine).
- the A monomers constituting the basic elements of the polymers of formula I can advantageously be identical.
- the A monomers constituting the basic elements of the polymers of formula I can advantageously be glucose.
- the number of monomers A defined in formula (I) by “a” can be such that the mass of said polymers of formula (I) is approximately between 2,000 and 6,000 daltons, for example which corresponds to at least 10 monomers of glucose.
- mass of said polymers of formula (I) may approximately between 3000 daltons and 6000 daltons, for example which corresponds to 12 to 20 glucose monomers.
- the number of monomers A defined in formula (I) by “a” can also be such that the mass of said polymers of formula (I) is less than approximately 2,500,000 daltons (which corresponds to 7,000 glucose monomers).
- the mass of said polymers of formula (I) may be from 3000 to 250,000 daltons, for example from 3000 to 6000 daltons, or for example from 20,000 to 250,000 daltons, or for example from 75,000 to 150 000 daltons.
- R 1 in the group -R 1 COOR 2 representing X, R 1 can be a C 1 to C 6 alkyl, for example a methyl, an ethyl, a butyl, a propyl, a pentyl, preferably a methyl group, and R 2 can be a bond, C1-C6 alkyl, for example methyl, ethyl, butyl, propyl, pentyl, a group R 21 R 22 in which R 21 is an anion and R 22 a selected cation in the group of alkali metals.
- the group X is the group of formula -R 1 COOR 2 in which R 1 is a methyl group -CH 2 - and R 2 is a group R 21 R 22 in which R 21 is an anion and R 22 is a cation chosen from the group of alkali metals, preferably the group X is a group of formula -CH 2 -COO or carboxym ethyl.
- R 9 may be a C1 to C6 alkyl, for example a methyl, an ethyl, a butyl, a propyl, a pentyl, preferably a methyl group
- R 10 can be a bond, a C 1 to C 6 alkyl, for example a methyl, an ethyl, a butyl, a propyl, a pentyl, a hexyl.
- the degree of substitution of all the monomers A by the groups X defined in general formula (I) by “x” can be from 10 to 150%, from 40 to 80%, and preferably of the order of 50% or 60%.
- R 3 may be a bond, a C1 to C6 alkyl, for example a methyl, a ethyl, a butyl, a propyl, a pentyl, preferably a methyl group
- R 5 may be a bond, a C1 to C6 alkyl, for example a methyl, an ethyl, a butyl, a propyl, a pentyl, preferably a methyl group
- R 7 can be a bond, a C 1 to C 6 alkyl, for example a methyl, an ethyl, a butyl, a propyl, a pentyl, preferably a methyl group
- R 4 , R 6 and Rs can be independently a hydrogen atom or an M + cation
- the Y group is the group of formula
- R7 is a bond and R8 is a selected alkali metal from the group comprising lithium, sodium, potassium, rubidium and cesium.
- the Y group is an -SO 3 , -SO3- Na + group .
- the degree of substitution of all of the A monomers by the Y groups defined in general formula (I) by "y” can be from 10 to 170%, from 30 to 150%, from 55 to 160%, from 55 at 85%, from 120 to 160%, and preferably of the order of 70, 140 or 150%.
- substitution rates means by a substitution rate "x" of 100%, the fact that each monomer A of the polymer of the invention statistically contains an X group.
- substitution rate of 100% is understood to mean the fact that each monomer of the polymer of the invention statistically contains a Y group.
- substitution rates greater than 100% reflect the fact that each monomer statistically bears more a group of the type considered; conversely, the substitution rates of less than 100% reflect the fact that each monomer statistically bears less than one group of the type considered.
- the polymers can also comprise functional chemical groups, designated Z, other than X and Y.
- the Z groups may be the same or different, and may independently be selected from the group consisting of amino acids, fatty acids, fatty alcohols, ceramides, or derivatives thereof, or nucleotide sequences of 'addressing, antibodies, antibody fragments.
- the Z groups can also represent identical or different active agents. These may be, for example, therapeutic agents, diagnostic agents, an anti-inflammatory, an antimicrobial, an antibiotic, a growth factor, an enzyme, a antioxidant compound, polyphenols, tannins, anthocyanins, lycopenes, terpenoids and resveratrol.
- the Z group can advantageously be a saturated or unsaturated fatty acid.
- a fatty acid chosen from the group comprising acetic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, acid arachidic, behenic acid, lignoceric acid, cerotic acid, myristoleic acid, palmitoleic acid, sapienic acid, oleic acid, elaidic acid, trans-vaccenic acid, l 'linoleic acid, linolelaidic acid, ⁇ -linolenic acid, g-linolenic acid, dihomo-y-linolenic acid, arachidonic acid, eicosapentaenoic acid, clupanodonic acid or acid docosahexaenoic.
- the fatty acid is acetic acid.
- the group Z can advantageously be an amino acid of the L or D series chosen from the group comprising alanine, asparagine, an aromatic chain, for example tyrosine, phenylalanine, tryptophan, thyroxine or histidine.
- the amino acid is phenylalanine.
- the group Z can be an antioxidant, for example vitamin A, C, E, B9, B6, glutathione, selenium, polyphenols, for example catechins, for example green tea, flavonoids, tannins, anthocyanins, for example red fruits, lycopenes, terpenoids and resveratrol.
- an antioxidant for example vitamin A, C, E, B9, B6, glutathione, selenium, polyphenols, for example catechins, for example green tea, flavonoids, tannins, anthocyanins, for example red fruits, lycopenes, terpenoids and resveratrol.
- the group Z can be antiaging compounds, for example retinoids, allantoins.
- the group Z can be antibodies, fragments of antibodies, for example Fab fragments. They may be, for example, antibodies and / or fragments of targeting antibodies, for example antibodies and / or fragments of antibodies capable of targeting the
- the Z groups can give the polymers additional biological or physicochemical properties.
- the Z groups can increase the solubility or the lipophilicity of said polymer, for example allowing better diffusion or tissue penetration.
- the Z groups can give the polymers additional biological or physicochemical properties.
- the polymers of the invention for example when the Z group is chosen from an antioxidant compound, an anti-aging compound, the polymers of the invention can advantageously convey these compounds and thus provide an additional and / or complementary biological effect.
- Polymers in which Z is present can correspond to the following formula II: Aa Xx Yy Zz (II) in which, A, X, Y, a, x, y are as defined above and z represents the degree of substitution by Z groups.
- the degree of substitution by Z groups represented by “z” can be from 1 to 50%, from 10 to 25%, preferably equal to 15, 20 or 25%.
- the X, Y and Z groups can be independently attached to the monomer A and / or independently attached to each other. When at least one of the X, Y and Z groups is independently attached to an X, Y and Z group other than the first, one of said X, Y or Z groups is attached to the A monomer.
- the Z groups can be covalently attached directly to the A monomers or covalently attached to the X and / or Y groups.
- the Z groups can also be conjugated to the polymers of formula AaXxYy by bonds other than covalent, for example by ionic bonds, for example via ionic interactions, hydrophilic bonds or hydrophobic bonds.
- the polymers of the invention can then constitute a Z vectorization system.
- the polymer may for example be a polymer chosen from the group comprising the compounds OTR4120, OTR41201, OTR41202, OTR41203, OTR41205, OTR41210 OTR41301,
- the polymer can be, for example, a polymer chosen from the group comprising the compounds OTR41201, OTR41202, OTR41203, OTR41205, OTR41210, OTR4120, OTR4122, OTR4125, OTR41301, OTR41302, OTR41303, OTR41305, O4TR31321310, OTR413110, OTR413110 , OTR415 with the characteristics mentioned in table 1 below
- Table 1 Polymers of the families Aa Xx Yy (I) and Aa Xx Yy Zz (II) in which A is glucose (PM 180D), X is CarboxyMethyl (PM 58 D) Y: SO3 (PM 80D) and Z is Acetate (PM 43D) or phenylalanine (PM 165D).
- the composition may comprise a concentration of 0.1 to 100 ⁇ g / ml by weight of biocompatible polymer based on the volume of the composition.
- the composition may comprise a concentration of 1 to 10 ⁇ g / ml_ by weight of biocompatible polymer relative to the total volume of the composition.
- the composition can be formulated and / or adapted according to its administration.
- the composition can be administered in order to deliver a dose of biocompatible polymer of 0.01 to 5 mg per kilogram of body weight, preferably 0.1 to 1.5 mg per kilogram of body weight at the frequency of one administration per week.
- the composition can be administered in order to deliver a dose of biocompatible polymer of 0.1 to 5 mg per kilogram of body weight, preferably 0.01 to 1.5 mg / kg to the frequency of daily or bi-weekly administration.
- the intake may be daily or twice weekly and between 0.5 pg / kg and 100 pg / kg.
- the biocompatible polymer may be at a concentration of 0.1 to 100 pg / ml by weight of biocompatible polymer relative to the total volume of the composition, preferably 1 to 20 ml.
- the administration can be effected through a route first to the brain, for example into the internal carotid artery.
- the biocompatible polymer can be at a concentration of 0.1 to 100 pg / ml by weight of biocompatible polymer relative to the total volume of the composition, preferably 5 to 20 ⁇ l.
- composition and / or polymer when administered intracranially, the administration can be carried out simultaneously or successively in different intracranial regions.
- the volume administered may range from 5 ⁇ l to 2 ml, for example 500 ⁇ l, for example 2 m.
- the volume administered may be isovolumetric, for example up to 2 ml.
- the delivered volume can be as described in
- the dose of biocompatible polymer can be between 0.0001 and 5 mg per kilogram of body weight.
- the intake may be daily.
- the molecular weight of the biocompatible polymer can range from 3000 D to 2,500,000 Daltons.
- the molecular weight of the biocompatible polymer can range from 3000 to 6000 Daltons, from 6000 to 2500000 Daltons, preferably from 20,000 to 250,000 Daltons and for example from 75,000 to 150,000 Daltons.
- the molecular weight of the biocompatible polymers present in the composition can be chosen depending on the route of administration of the composition and the frequency of administration.
- the molecular weight of the biocompatible polymer can be comprised from 3000 to 200,000 Daltons depending on the level of damage to the lesion of the blood-brain barrier, preferably 3000. at 150,000 Daltons.
- the molecular weight of the biocompatible polymers present in the composition can be chosen according to the alteration and / or the state of the blood brain barrier.
- the molecular weight of the biocompatible polymer can be between 3000 and 200000
- Daltons preferably 70,000 to 150,000 Daltons.
- the molecular weight of the biocompatible polymer can be adapted following and / or according to the progressive repair of the blood-brain barrier.
- the molecular weight of the biocompatible polymer can range from 3000 to 200000 Daltons, preferably 70,000 to 150,000 Daltons. Subsequently, the molecular weight used can be reduced eg 3000 to 100,000 Daltons, preferably 10,000 to 70,000 Daltons.
- the composition may further comprise a hydrogel.
- hydrogel any suitable hydrogel known to a person skilled in the art. It can be, for example, a hydrogel chosen from the group comprising hyaluronic acid or a derivative thereof, biocompatible hydrogels used in filling the brain space after injury. It may be, for example, the hydrogel described in the document Vladimir A. Kornev et al: Hydrogel-assisted neuroregeneration approaches towards brain injury therapy: A state-of-the-art review. Computational and Structural Biotechnology Journal 16 j.csbj.2018.10.011 [24] and / or described in Gopalakrishnan A, Shankarappa SA, Rajanikant GK. Hydrogel Scaffolds: Towards Restitution of Ischemia Stroke-lnjured Brain 2019 Feb; 10 (1): 1 -18 [25]
- composition may comprise a hydrogel concentration of 0.1% to 5%, preferably 0.5% to 2.5% by weight of hydrogel.
- the composition may comprise hyaluronic acid and / or at least one hydrogel and / or a mixture thereof
- hyaluronic acid any hyaluronic acid known to those skilled in the art, for example a non-sulfated linear glycosaminoglycan composed of repeating units of D-glucuronic acid and of N-acetyl-D. -glucosamine.
- hyaluronic acid in its acid form or in the form of salt (hyaluronate), of crosslinked hyaluronic acid HA is a non-sulfated linear glycosaminoglycan composed of repeating units of D-glucuronic acid and N-acetyl-D-glucosamine (Tammi R., Agren UM., Tuhkanen AL., Tammi M. Hyaluronan metabolism in skin. Progress in Histochemistry & Cytochemistry. 29 (2): 1-81, 1994 [26]) . It can be by example of hyaluronic acid having average molecular weight fractions of 5,000 to 3,000,000 Dalton, preferably between 50,000 and 2,000,000 Dalton.
- hyaluronic acid can be obtained by any method known to those skilled in the art. It may be, for example, methods described in the journal Hyaluronan fragments: an information-rich System (R. Stern et al., European Journal of Cell Biology 58 (2006) 699-715 [27]). It may also be natural or modified hyaluronic acid, commercially available, whatever their designations and / or molecular weight, for example commercial hyaluronic acid chosen from Hyactive CPN; Cristalhyal; Nutra HA; Oligo HA; D Factor; Hyaluderm; juvelift; Restylane; Revitacare without this list being exhaustive.
- the composition can comprise a concentration of 0.1 to 5% by weight of hyaluronic acid relative to the total weight of the composition.
- the composition may comprise a concentration of 0.5% to 2.5% by weight of hyaluronic acid relative to the total weight of the composition.
- the hydrogel composition can be formulated for a direct intracranial administration, for local intracranial injection, in particular via an intra-arterial route, the composition can comprise a concentration of 1 to 10 mg / ml in weight of hyaluronic acid relative to the total volume of the composition.
- the term “pharmaceutical composition” means any form of pharmaceutical composition known to a person skilled in the art.
- the pharmaceutical composition can be for example an injectable solution. It can be for example an injectable solution, for example for a local or systemic injection, for example in serum physiological, in injectable glucose solution, in the presence of excipients, for example dextrans, for example at concentrations known to those skilled in the art, for example from micrograms to a few milligrams per ml_.
- the pharmaceutical composition may for example be a medicament intended for oral administration chosen from the group comprising a liquid formulation, an effervescent oral dosage form, an oral powder, a multiparticulate system, an orodispersible dosage form.
- the pharmaceutical composition when it is for oral administration, it can be in the form of a liquid formulation chosen from the group comprising a solution, a syrup, a suspension or an emulsion.
- the pharmaceutical composition when it is in the form of an effervescent oral dosage form, it may be in a form selected from the group comprising tablets, granules, powders.
- the pharmaceutical composition when the pharmaceutical composition is in the form of an oral powder or a multiparticulate system, it can be in a form selected from the group consisting of beads, granules, mini tablets and microgranules.
- the pharmaceutical composition when in the form of an orodispersible dosage form, it may be in a form selected from the group consisting of orodispersible tablets, lyophilized wafers, thin films, a chewable tablet, a tablet, a capsule. or a medical chewing gum.
- the pharmaceutical composition can be a pharmaceutical composition for oral administration, for example buccal and / or sublingual, for example chosen from the group comprising buccal or sublingual tablets, lozenges, drops, a solution for sprays.
- the pharmaceutical composition can be a pharmaceutical composition for topical or transdermal administration, for example chosen from the group comprising ointments, creams, gels, lotions, patches and foams.
- the pharmaceutical composition can be a pharmaceutical composition for nasal administration, for example chosen from the group comprising nasal drops, nasal spray, nasal powder.
- the pharmaceutical composition can be a pharmaceutical composition for parenteral administration, for example subcutaneous, intramuscular, intravenous, intraarterial, intracranial, intrathecal.
- the pharmaceutical composition can be a pharmaceutical composition for intra-arterial and / or intracranial administration.
- composition of the present invention may also comprise at least one other active ingredient, particularly another therapeutically active ingredient, for example for simultaneous, separate or staggered use depending on the galenic formulation used.
- This other ingredient can be for example an active ingredient used for example in the treatment of opportune diseases which may develop in a patient having an alteration and / or damage to the blood brain barrier.
- It can also be pharmaceutical products known to those skilled in the art, for example antibiotics, anti-inflammatories, anticoagulants, neuroprotectors, acetylcholinesterase inhibitors, antidepressants, antivirals
- the composition can be, for example, administered daily, twice daily and weekly. For example, this may be once a day, twice a day or more.
- the composition can be, for example, administered over a period of 1 day to 3 months, for example for 2 months.
- the composition can be administered over a period of 3 months with a frequency of administration every day.
- a subject of the present invention is also the use of a pharmaceutical composition comprising a biocompatible polymer of formula AaXxYy (I) or AaXxYyZz (II) for the manufacture of a medicament for the protection and / or repair / restoration of the barrier. hematoencephalic.
- the biocompatible polymer is as defined above.
- drug is understood to mean a pharmaceutical composition as defined above.
- the inventors have demonstrated that the biocompatible polymer makes it possible, surprisingly, both to accelerate the repair / reformation of the Blood-Brain Barrier when the latter is altered both at the structural and / or functional level.
- the biocompatible polymer advantageously and surprisingly allows a functional restoration of the Blood-Brain Barrier, in particular a restoration of its permeability, whatever the cause and / or the origin of its modification and / or alteration.
- Figure 1 shows the change in the permeability of the blood-brain barrier (BBB) after an ischemic stroke as a function of time, the ordinate corresponds to the patency and the abscissa the time in hours.
- BBB blood-brain barrier
- FIG. 2 represents an example of a structure of a biocompatible polymer, for example the structure of the compound OTR4132.
- Figure 3 is a bar graph showing the evolution of BBB permeability in regions of interest studied by MRI.
- the abscissa corresponds to the time in hours or days after cerebral ischemia: 1 h, 3 h, 24 h, 48 h, and 7 days after ischemia.
- the values obtained correspond to the mean +/- standard deviation.
- the ordinate corresponds to the volume of modification of the integrity of the
- Figure 4 is a bar graph showing the permeability of BBB after cerebral ischemia by Evans blue staining.
- the ordinate represents the amount of Evans blue in pg / g of brain tissue as a function of the ischemic area of the central nervous system, namely ipsalateral or contralateral.
- the values obtained for rats for which a composition comprising a biocompatible polymer (OTR4132) was administered are represented by shaded bars, the values obtained for rats for which a control composition was administered are represented by black bars.
- Example 1 Use of a biocompatible polymer for the treatment of an impaired blood brain barrier and functional restoration of the blood brain barrier
- OTR4131 is a compound comprising a radical Z which is a fatty acid, namely acetic acid as described in Frescaline G. et al., Tissue Eng Part A. 2013 Jul; 19 (13-14): 1641 -53. doi: 10.1089 / ten.TEA.2012.0377 [30]), Randomized controlled trial demonstrates the benefit of RGTA® based matrix therapy to treat tendinopathies in racing horses. Jacquet-Guibon S, Toys AG, Coudry V, Crevier-Denoix N, Leroy S, Sineriz F, Chiappini F, Barritault D, Denoix JM. PLoS One. 2018 Mar 9; 13 (3): e0191796.
- CVA cerebral vascular accident
- a rat stroke model was used. It was a 1 hour cerebral ischemia, obtained by occlusion of the cerebral artery intraluminal followed by reperfusion.
- the rats used were male Sprague Dawley rats with an average weight of 300-350g.
- the number of rats used was four to six rats per group per time.
- Figure 1 shows the change in permeability over time in the model used as described in Abdullahi et al., 2018.
- the BBB permeability assessment was performed by MRI after an injection of a contrast agent, DOTAREM®, at different times: 1 h, 3 h, 24 h, 48 h, and 7 days after cerebral ischemia.
- This contrast agent does not cross the BBB under physiological conditions.
- the contrast agent was injected intravenously, via the femoral vein.
- the amount of contrast agent administered by injection was 200 pmol / kg (DOTAREM (trademark), Guerbet S. A.).
- the biocompatible polymer OTR4132 was administered 1 hour after cerebral ischemia, the volume of composition administered comprising a concentration of 0.5 mg / kg of OTR4132 was 300 ⁇ l per tail vein.
- Rats i.e. four to five animals per group per time (were treated with a control solution i.e. physiological saline (0.9% NaCl saline solution).
- the control solution was administered in an identical manner to the composition comprising the compound OTR4132, namely 1 hour after the cerebral ischemia, the volume of composition administered was 250 ⁇ l administered by the femoral vein.
- the observation of the permeability and diffusion of the contrast agent was carried out by observation on images obtained by MRI.
- the regions of the central nervous system observed were located in the cerebral hemisphere affected by ischemia as well as the healthy contralateral hemisphere.
- the determination of the diffusion of the contrast agent on the obtained images was carried out by MRI analysis using appropriate software (Image J (trademark) (Wayne Rasband, NIMH, Maryland, USA)).
- Image J trademark
- the results concerning the diffusion of the contrast agent and / or the permeability of the Blood Brain Barrier are shown in Figure 3.
- the rats given the contrast agent and the control solution show an increased permeability of the Blood Brain Barrier 24 hours, 48 hours and 7 days after the stroke (black bars) , these results were in agreement with those obtained in the state of the art (Garrigue et al. 2016 [6]).
- This diagram also clearly and surprisingly demonstrates that the treatment of the rats with the biocompatible polymer OTR4132 makes it possible to significantly reduce the permeability of the BBB at 24 and 48 h post ischemia in the group of rats treated with RGTA compared to the rats of the ischemic group having received the control solution.
- results demonstrated a statistically significant difference between the rats treated with a control solution compared to the rats treated with a composition comprising a biocompatible polymer according to the invention (ANOVA followed by a post-hoc HSD test by Tukey p ⁇ 0.05).
- results obtained and illustrated in FIG. 3 clearly demonstrate that the use of biocompatible polymers according to the invention makes it possible to preserve the integrity of the BBB after a stroke.
- these results clearly demonstrate that the use of a biocompatible polymer according to the invention makes it possible both to protect the BBB, to promote its repair and, in the case where the physiological properties of the BBB are altered / modified, to restore the physiological properties and / or reduce their modifications.
- the permeability of BBB was measured by staining with Evans blue after induction of cerebral ischemia according to the method described in the document Hone et al., 2018 [7].
- the rats used were male Sprague Dawley rats with an average weight of 300-350g, the experiment was carried out on 11 rats including five rats for which Evans blue, which does not cross the BBB under physiological conditions, was injected intravenously at a concentration of 2%, 72 h after cerebral ischemia, the volume injected was 4 ml / kg, ie from 1.2 to 1.4 ml for a rat weighing 300 to 350 g respectively.
- RGTA OTR4132 with a molecular weight of 100,000 to 150,000 Da, administered 1 hour after cerebral ischemia, the volume of composition administered comprising a dose of 2.22 pg of OTR4132 was 50mI intraarterially through the internal carotid.
- mice Five rats had been treated with a control solution, namely physiological serum (0.9% NaCl saline solution) administered in an identical manner to the composition comprising the compound OTR4132, namely 1 hour after the cerebral ischemia, the volume of composition administered were 50mI intraarterially through the internal carotid.
- physiological serum 0.9% NaCl saline solution
- tissue Evans blue present in the recovered supernatant was then quantified spectrophotometrically with a measurement at 610 nm.
- FIG. 4 represents the results obtained as a function of the individuals.
- composition according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz advantageously makes it possible to protect the BBB and / or to restore the physiological properties of the BBB.
- this example clearly demonstrates that examples of composition according to the invention comprising a polymer of formula AaXxYy or AaXxYyZz makes it possible to preserve the integrity of the BBB after a stroke.
- these results clearly demonstrate that the use of a biocompatible polymer according to the invention makes it possible both to protect the BBB, to promote its repair, and, in the cases where the physiological properties of the BBB are altered / modified, to restore the physiological properties and / or to reduce their modifications.
- Example 2 Use of a biocompatible polymer for the treatment of an altered Blood-brain barrier and functional restoration of the Blood-brain barrier
- the dose administered was 3 mg / day / for 75 kg or 40 pg / kg / day.
- an improvement in cognitive performance was observed by neurologists and also the treating or referring physician and his family.
- Another individual an 85-year-old woman with major memory problems, in particular difficulty in reading, in recognizing individuals, especially close relatives (families), inability to write, etc.
- the individual was noted as Alzheimer's with handicap coefficient, thus implicating an alteration of the Blood-Brain Barrier was treated by twice-weekly sublingual intake of a dose of 300 microL at 100 pg / mL of OTR4120 (weighing around 60 kg) or 0.5 pg (0.5 pg / kg biweekly).
- an improvement in cognitive functions, social relations for example with his environment, particularly family and medical, able to make calls, move around, see friends again, play scrabble etc.
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3141923A CA3141923A1 (fr) | 2019-05-27 | 2020-04-30 | Composition pour la protection et la reparation de la barriere hematoencephalique (bhe) |
JP2021570515A JP2022534278A (ja) | 2019-05-27 | 2020-04-30 | 血液脳関門(bbb)の保護及び修復のための組成物 |
EP20721621.9A EP3976060A1 (fr) | 2019-05-27 | 2020-04-30 | Composition pour la protection et la reparation de la barriere hematoencephalique (bhe) |
AU2020284406A AU2020284406A1 (en) | 2019-05-27 | 2020-04-30 | Composition for the protection and repair of the blood brain barrier |
BR112021023737A BR112021023737A2 (pt) | 2019-05-27 | 2020-04-30 | Composição farmacêutica e uso |
CN202080047142.7A CN114206354B (zh) | 2019-05-27 | 2020-04-30 | 用于保护和修复血脑屏障(bbb)的组合物 |
KR1020217042420A KR20220042310A (ko) | 2019-05-27 | 2020-04-30 | 혈액-뇌 장벽(bbb)의 보호 및 복구용 조성물 |
US17/595,818 US20220152089A1 (en) | 2019-05-27 | 2020-04-30 | Composition for the protection and repair of the blood brain barrier |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FRFR1905566 | 2019-05-27 | ||
FR1905566A FR3096579B1 (fr) | 2019-05-27 | 2019-05-27 | composition pour la protection et la reparation de la barriere hematoencephalique (BHE) |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020239356A1 true WO2020239356A1 (fr) | 2020-12-03 |
Family
ID=68138337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2020/062081 WO2020239356A1 (fr) | 2019-05-27 | 2020-04-30 | Composition pour la protection et la reparation de la barriere hematoencephalique (bhe) |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220152089A1 (fr) |
EP (1) | EP3976060A1 (fr) |
JP (1) | JP2022534278A (fr) |
KR (1) | KR20220042310A (fr) |
CN (1) | CN114206354B (fr) |
AU (1) | AU2020284406A1 (fr) |
BR (1) | BR112021023737A2 (fr) |
CA (1) | CA3141923A1 (fr) |
FR (1) | FR3096579B1 (fr) |
WO (1) | WO2020239356A1 (fr) |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0464759A2 (fr) * | 1990-07-03 | 1992-01-08 | Hoechst Aktiengesellschaft | Polysaccharides sulfatés pour la prophylaxie à long terme de maladies causées par des virus ou virus non conventionnels |
WO1995026739A2 (fr) * | 1994-03-30 | 1995-10-12 | Universite Paris Val De Marne | Utilisation de dextrane substitue pour le traitement des lesions du systeme nerveux et fractions enrichies en herapane sulfate |
WO2001051003A2 (fr) * | 2000-01-10 | 2001-07-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Utilisation de conjugues de lipides dans le traitement de maladies |
US20010023246A1 (en) * | 1994-03-30 | 2001-09-20 | Denis Barritault | Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate |
WO2003046014A1 (fr) * | 2001-11-29 | 2003-06-05 | Organes, Tissus : Regeneration, Reparation, Remplacement-Otr3 | Procede de sulfonation de composes comprenant des groupements hydroxyles (oh) libres ou des amines primaires ou secondaires |
US6689741B2 (en) | 1998-07-21 | 2004-02-10 | Denis Barritault | Biocompatible polymers, process for their preparation and compositions containing them |
US20090062208A1 (en) | 2007-02-06 | 2009-03-05 | Mochly-Rosen Daria D | Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-PKC inhibitor |
CN101632728A (zh) | 2008-07-21 | 2010-01-27 | 河北以岭医药研究院有限公司 | 一种中药组合物在制备保护血脑屏障的药物中的应用 |
WO2011156445A1 (fr) * | 2010-06-08 | 2011-12-15 | University Of Utah Research Foundation | Applications de hyaluronane partiellement ou entièrement sulfaté |
US20140301972A1 (en) | 2003-10-28 | 2014-10-09 | Denis Barritault | Use of biocompatible polymers for the preparation of a composition or a medical device |
CN105148276A (zh) | 2015-09-22 | 2015-12-16 | 深圳市第二人民医院 | 抑制Claudin-5降解阻止缺血性血脑屏障损伤的保护剂 |
EP3097928A1 (fr) * | 2015-05-28 | 2016-11-30 | Organes Tissus Régénération Réparation Remplacement | Composition pour le traitement des lesions cerebrales |
WO2018207792A1 (fr) | 2017-05-12 | 2018-11-15 | 花王株式会社 | Agent de protection de barrière hémato-encéphalique |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3097922A1 (fr) * | 2015-05-28 | 2016-11-30 | Denis Barritault | Composition pour le traitement des lesions tissulaires |
-
2019
- 2019-05-27 FR FR1905566A patent/FR3096579B1/fr active Active
-
2020
- 2020-04-30 AU AU2020284406A patent/AU2020284406A1/en active Pending
- 2020-04-30 KR KR1020217042420A patent/KR20220042310A/ko unknown
- 2020-04-30 US US17/595,818 patent/US20220152089A1/en active Pending
- 2020-04-30 WO PCT/EP2020/062081 patent/WO2020239356A1/fr unknown
- 2020-04-30 CN CN202080047142.7A patent/CN114206354B/zh active Active
- 2020-04-30 CA CA3141923A patent/CA3141923A1/fr active Pending
- 2020-04-30 EP EP20721621.9A patent/EP3976060A1/fr active Pending
- 2020-04-30 BR BR112021023737A patent/BR112021023737A2/pt unknown
- 2020-04-30 JP JP2021570515A patent/JP2022534278A/ja active Pending
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0464759A2 (fr) * | 1990-07-03 | 1992-01-08 | Hoechst Aktiengesellschaft | Polysaccharides sulfatés pour la prophylaxie à long terme de maladies causées par des virus ou virus non conventionnels |
WO1995026739A2 (fr) * | 1994-03-30 | 1995-10-12 | Universite Paris Val De Marne | Utilisation de dextrane substitue pour le traitement des lesions du systeme nerveux et fractions enrichies en herapane sulfate |
US20010023246A1 (en) * | 1994-03-30 | 2001-09-20 | Denis Barritault | Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate |
US6689741B2 (en) | 1998-07-21 | 2004-02-10 | Denis Barritault | Biocompatible polymers, process for their preparation and compositions containing them |
WO2001051003A2 (fr) * | 2000-01-10 | 2001-07-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Utilisation de conjugues de lipides dans le traitement de maladies |
US7396923B2 (en) | 2001-11-29 | 2008-07-08 | Organes, Tissues : Regeneration, Reparation, Remplacement- Otr3 | Method for the sulfonation of compounds comprising free hydroxyl (OH) groups or primary or secondary amines |
WO2003046014A1 (fr) * | 2001-11-29 | 2003-06-05 | Organes, Tissus : Regeneration, Reparation, Remplacement-Otr3 | Procede de sulfonation de composes comprenant des groupements hydroxyles (oh) libres ou des amines primaires ou secondaires |
US20140301972A1 (en) | 2003-10-28 | 2014-10-09 | Denis Barritault | Use of biocompatible polymers for the preparation of a composition or a medical device |
US20090062208A1 (en) | 2007-02-06 | 2009-03-05 | Mochly-Rosen Daria D | Methods for maintaining blood-brain barrier integrity in hypertensive subjects using a delta-PKC inhibitor |
CN101632728A (zh) | 2008-07-21 | 2010-01-27 | 河北以岭医药研究院有限公司 | 一种中药组合物在制备保护血脑屏障的药物中的应用 |
WO2011156445A1 (fr) * | 2010-06-08 | 2011-12-15 | University Of Utah Research Foundation | Applications de hyaluronane partiellement ou entièrement sulfaté |
EP3097928A1 (fr) * | 2015-05-28 | 2016-11-30 | Organes Tissus Régénération Réparation Remplacement | Composition pour le traitement des lesions cerebrales |
CN105148276A (zh) | 2015-09-22 | 2015-12-16 | 深圳市第二人民医院 | 抑制Claudin-5降解阻止缺血性血脑屏障损伤的保护剂 |
WO2018207792A1 (fr) | 2017-05-12 | 2018-11-15 | 花王株式会社 | Agent de protection de barrière hémato-encéphalique |
Non-Patent Citations (38)
Title |
---|
ABDULLAHI WTRIPATHI DRONALDSON PT: "Blood-Brain Barrier Dysfunction in Ischemic Stroke: Targeting Tight Junctions and Transporters for Vascular Protection", AM J PHYSIOL CELL PHYSIOL., 27 June 2018 (2018-06-27) |
BARRITAULT DDESGRANGES PMEDDAHI-PELLÉ ADENOIX JMSAFFAR JL, JOINT BONE SPINE, vol. 84, no. 3, May 2017 (2017-05-01), pages 283 - 292 |
BARRITAULT DDESGRANGES PMEDDAHI-PELLÉ ADENOIX JMSAFFAR JL, JOINT BONE SPINE., vol. 84, no. 3, May 2017 (2017-05-01), pages 283 - 292 |
BARRITAULT DGILBERT-SIRIEIX MRICE KLSINERIZ FPAPY-GARCIA DBAUDOUIN CDESGRANGES PZAKINE GSAFFAR JLVAN NECK J.: "RGTA(@) or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients", GLYCOCONJ J., vol. 34, no. 3, June 2017 (2017-06-01), pages 325 - 338, XP036255501, DOI: 10.1007/s10719-016-9744-5 |
BLANEY, S. M.BALIS, F. M.BERG, S.ARNDT, C. A.HEIDEMAN, R.GEYER, J. R.AIKIN, A.: "Intrathecal mafosfamide: a preclinical pharmacology and phase I trial", JOURNAL OF CLINICAL ONCOLOGY, vol. 23, no. 7, 2005, pages 1555 - 1563 |
CARDOSO, F. L.BRITES, D.BRITO, M. A.: "Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches", BRAIN RESEARCH REVIEWS, vol. 64, no. 2, 2010, pages 328 - 363, XP027260716 |
ERICKSON MABANKS WA: "Neuroimmune Axes of the Blood-Brain Barriers and Blood-Brain Interfaces: Bases for Physiological Regulation, Disease States, and Pharmacological Interventions", PHARMACOL REV., vol. 70, no. 2, April 2018 (2018-04-01), pages 278 - 314 |
FRESCALINE G. ET AL., TISSUE ENG, vol. 19, no. 13-14, July 2013 (2013-07-01), pages 1641 - 53 |
GARRIGUE PGIACOMINO LBUCCI CMUZIO VFILANNINO MASABATIER FDIGNAT-GEORGE FPISANO PGUILLET B.: "Single photon émission computed tomography imaging of cerebral blood flow, blood-brain barrier disruption, and apoptosis time course after focal cerebral ischemia in rats", INT J STROKE, vol. 11, no. 1, January 2016 (2016-01-01), pages 117 - 26 |
GOPALAKRISHNAN ASHANKARAPPA SARAJANIKANT GK, HYDROGEL SCAFFOLDS: TOWARDS RESTITUTION OF ISCHEMIC STROKE-INJURED BRAIN, vol. 10, no. 1, February 2019 (2019-02-01), pages 1 - 18 |
HOLMES BBDEVOS SLKFOURY NLI MJACKS RYANAMANDRA KOUIDJA MOBRODSKY FMMARASA JBAGCHI DP, PROC NATL ACAD SCI U S A., vol. 110, no. 33, 13 August 2013 (2013-08-13), pages E3138 - 47 |
HOLMES BBDEVOS SLKFOURY NLI MJACKS RYANAMANDRA KOUIDJA MOBRODSKY FMMARASA JBAGCHI DP, PROC NATL ACAD SCI USA., vol. 110, no. 33, 13 August 2013 (2013-08-13), pages E3138 - 47 |
HONE EAHU HSPROWLS SAFAROOQI IGRASMICK KLOCKMAN PR ET AL.: "Biphasic Blood-Brain Barrier Openings after Stroke", NEUROL DISORD STROKE INT., vol. 1, no. 2, 2018, pages 1011 |
HYNES RONABA A: "Overview of the matrisome--an inventory of extracellular matrix constituents and functions", COLD SPRING HARB PERSPECT BIOL., vol. 4, no. 1, 1 January 2012 (2012-01-01), pages a004903 |
JACQUET-GUIBON SDUPAYS AGCOUDRY VCREVIER-DENOIX NLEROY SSINERIZ FCHIAPPINI FBARRITAULT DDENOIX JM, PLOS ONE, vol. 13, no. 3, 9 March 2018 (2018-03-09), pages e0191796 |
KHELIF, Y.TOUTAIN, J.QUITTET, M. S.CHANTEPIE, S.LAFFRAY, X.VALABLE, S.BARRITAULT, D.: "A heparan sulfate-based matrix therapy reduces brain damage and enhances functional recovery following stroke", THERANOSTICS, vol. 8, no. 21, 2018, pages 5814 |
MARKS JR, W. J.OSTREM, J. L.VERHAGEN, L.STARR, P. A.LARSON, P. S.BAKAY, R. A.BARTUS, R. T.: "Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial", THE LANCET NEUROLOGY, vol. 7, no. 5, 2008, pages 400 - 408, XP022609985, DOI: 10.1016/S1474-4422(08)70065-6 |
MÔBIUS-WINKLER, S.LINKE, A.ADAMS, V.SCHULER, G.ERBS, S.: "How to improve endothelial repair mechanisms: the lifestyle approach", EXPERT REVIEW OF CARDIOVASCULAR THERAPY, vol. 8, no. 4, 2010, pages 573 - 580 |
OUIDJA MOPETIT EKERROS MEIKEDA YMORIN CCARPENTIER GBARRITAULT DBRUGÈRE-PICOUX JDESLYS JPADJOU K, BIOCHEM BIOPHYS RES COMMUN., vol. 363, no. 1, 9 November 2007 (2007-11-09), pages 95 - 100 |
OUIDJA MOPETIT EKERROS MEIKEDA YMORIN CCARPENTIER GBARRITAULT DBRUGÈRE-PICOUX JDESLYS JPADJOU K, BIOCSHEM BIOPHYS RES COMMUN., vol. 363, no. 1, 9 November 2007 (2007-11-09), pages 95 - 100 |
PESCHILLO SDIANA FBERGE JMISSORI P: "A comparison of acute vascular damage caused by ADAPT versus a stent retriever device after thrombectomy in acute ischemic stroke: a histological and ultrastructural study in an animal model", J NEUROINTERV SURG., vol. 9, no. 8, August 2017 (2017-08-01), pages 743 - 749 |
PETIT E. ET AL., BIOMACROMOLECULES, vol. 5, no. 2, March 2004 (2004-03-01), pages 445 - 52 |
R. STERN ET AL., EUROPEAN JOURNAL OF CELL BIOLOGY, vol. 58, 2006, pages 699 - 715 |
RAFII, M. S.BAUMANN, T. L.BAKAY, R. AOSTROVE, J. M.SIFFERT, J.FLEISHER, A. S.CHU, Y.: "A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease", ALZHEIMER'S & DEMENTIA, vol. 10, no. 5, 2014, pages 571 - 581 |
RAJENDRAN PRENGARAJAN TTHANGAVEL JNISHIGAKI YSAKTHISEKARAN DSETHI GNISHIGAKI I: "The vascular endothelium and human diseases", INT J BIOL SCI., vol. 9, no. 10, 9 November 2013 (2013-11-09), pages 1057 - 69 |
RONALDSON, P. T.DAVIS, T. P.: "Targeting transporters: promoting blood-brain barrier repair in response to oxidative stress injury", BRAIN RESEARCH, vol. 1623, 2015, pages 39 - 52, XP029268050, DOI: 10.1016/j.brainres.2015.03.018 |
SHARIF YJUMAH FCOPLAN LKROSSER ASHARIF KTUBBS RS: "The Blood Brain Barrier: A Review of its Anatomy and Physiology in Health and Disease", CLIN ANAT., 10 April 2018 (2018-04-10) |
SIFAT, A. E.VAIDYA, B.ABBRUSCATO, T. J.: "Blood-brain barrier protection as a therapeutic strategy for acute ischemic stroke", THE AAPS JOURNAL, vol. 19, no. 4, 2017, pages 957 - 972, XP036262888, DOI: 10.1208/s12248-017-0091-7 |
STEINER EENZMANN GULYCK RLIN SRUEGG MAKROGER SENGELHARDT B: "The heparan sulfate proteoglycan agrin contributes to barrier properties of mouse brain endothelial cells by stabilizing adherens junctions", CELL TISSUE RES, vol. 358, 2014, pages 465 - 479 |
SWEENEY MDSAGARE APZLOKOVIC BV: "Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders", NAT REV NEUROL., vol. 14, no. 3, March 2018 (2018-03-01), pages 133 - 150 |
TAMMI R.AGREN UM.TUHKANEN AL.TAMMI M.: "Hyaluronan metabolism in skin", PROGRESS IN HISTOCHEMISTRY & CYTOCHEMISTRY, vol. 29, no. 2, 1994, pages 1 - 81 |
TENG DPANNELL JSRENNERT RCLI JLI YSWONG VWCHIEN SKHALESSI AA: "Endothelial trauma from mechanical thrombectomy in acute stroke: in vitro live-cell platform with animal validation", STROKE, vol. 46, no. 4, April 2015 (2015-04-01), pages 1099 - 106 |
THOMSEN MSROUTHE LJMOOS T: "The vascular basement membrane in the healthy and pathological brain", J CEREB BLOOD FLOW METAB, vol. 37, no. 10, October 2017 (2017-10-01), pages 3300 - 3317 |
VLADIMIR A. KORNEV ET AL.: "Hydrogel-assisted neuroregeneration approaches towards brain injury therapy: A state-of-the-art review", COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL |
WARREN, KE BEYOND: "the Blood: Brain Barrier: The Importance of Central Nervous System (CNS) Pharmacokinetics for the Treatment of CNS Tumors", INCLUDING DIFFUSE INTRINSIC PONTINE GLIOMA FRONT. ONCOL., 3 July 2018 (2018-07-03), Retrieved from the Internet <URL:https://doi.org/10.3389/fonc.20.> |
WILGUS A.: "Growth Factor-Extracellular Matrix Interactions Regulate Wound Repair", ADVANCES IN WOUND CARE, vol. 1, no. 6, 2012, pages 249 - 254 |
YASUNORI I. ET AL., BIOMATERIALS, vol. 32, 2011, pages 769e776 |
YASUNORI I. ET AL.: "2011", BIOMATERIALS, vol. 32, pages 769e776 |
Also Published As
Publication number | Publication date |
---|---|
FR3096579A1 (fr) | 2020-12-04 |
CN114206354A (zh) | 2022-03-18 |
BR112021023737A2 (pt) | 2022-02-01 |
CA3141923A1 (fr) | 2020-12-03 |
JP2022534278A (ja) | 2022-07-28 |
KR20220042310A (ko) | 2022-04-05 |
EP3976060A1 (fr) | 2022-04-06 |
CN114206354B (zh) | 2023-12-29 |
FR3096579B1 (fr) | 2023-05-05 |
US20220152089A1 (en) | 2022-05-19 |
AU2020284406A1 (en) | 2022-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6842916B2 (ja) | 非発酵性糖と組み合わせたポリグルコサミン誘導体の経口製剤 | |
CA2930489C (fr) | Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl | |
Kantak et al. | Analysis of clinical trials on biomaterial and therapeutic applications of chitosan: A review | |
EP3030225B1 (fr) | Compositions à libération continue à base d'acide hyaluronique, et leurs applications thérapeutiques | |
EP3626256B1 (fr) | Composition pour le traitement des lésions tissulaires | |
JP2017523983A (ja) | 生理活性で、ナノカプセル化された抗酸化物質の送達 | |
EP3302573B1 (fr) | Composition pour le traitement des lesions cerebrales | |
WO2022006413A2 (fr) | Compositions comprenant du cannabidiol et des flavanones | |
EP1162937B1 (fr) | Compositions a base d'un sulfate de chondroitine et de chitosan pour prevenir ou traiter les affections rhumatologiques par voie generale | |
US20220313659A1 (en) | Methods for Increasing the Bioavailability of OTC and Pharmaceutical Drugs | |
EP3976060A1 (fr) | Composition pour la protection et la reparation de la barriere hematoencephalique (bhe) | |
CN113384541B (zh) | 一种用于防治早期神经退行性疾病的鼻腔纳米自噬诱导剂及其制备方法 | |
EP3694505B1 (fr) | Composé et composition pour utilisation dans le traitement préventif et/ou curatif des maladies du système nerveux central caractérisées par un déclin de la plasticité neuronale, en particulier caractérisées par un déclin de la plasticité synaptique | |
OA20894A (fr) | Composition pour la protection et la réparation de la barrière hématoencéphalique (BHE). | |
WO2021181037A1 (fr) | Composition pour le traitement de lesions du systeme respiratoire | |
EP1317922B1 (fr) | Preparation antipyretique renfermant du xylitol | |
EA046226B1 (ru) | Применение фармацевтической композиции в качестве лекарственного средства для защиты и/или репарации/восстановления гематоэнцефалического барьера | |
FR3048616A1 (fr) | Polycomplexes de composes poly-lysine pour la prevention et/ou la lutte contre la sclerose laterale amyotrophique | |
Mutreja et al. | Lipid nanoparticle-based formulations for high-performance dentistry applications | |
WO2021181010A1 (fr) | Composition pour le traitement de lesions du système respiratoire | |
Sagar et al. | Recent Development in the Management of Osteoarthritis–Overview of Nanoformulation Approaches | |
Duan et al. | Glucose-modified BSA/procyanidin C1 NPs penetrate the blood-brain barrier and alleviate neuroinflammation in Alzheimer's disease models | |
Carvalho | Intership Reports and Monograph entitled" Nanocarrier-based strategies to improve the topical treatment of psoriasis" | |
Perchyonok et al. | Bioactive-functionalized interpenetrating network hydrogel (BIOF-IPN) | |
Greene | Engineering Formulations for the Treatment of Periodontal Disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20721621 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3141923 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021570515 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021023737 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2020284406 Country of ref document: AU Date of ref document: 20200430 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020721621 Country of ref document: EP Effective date: 20220103 |
|
ENP | Entry into the national phase |
Ref document number: 112021023737 Country of ref document: BR Kind code of ref document: A2 Effective date: 20211125 |